FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892367714> ?p ?o ?g. }

• W2892367714 endingPage "2995" @default.
• W2892367714 startingPage "2988" @default.
• W2892367714 abstract "MAVERICC compared the efficacy and safety of modified leucovorin/5-fluorouracil/oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus bevacizumab (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC).Patients and Methods: MAVERICC was a global, randomized, open-label, phase II study. Primary objectives were to assess associations between (i) excision repair cross-complementing 1 (ERCC1) expression with progression-free survival (PFS), and (ii) plasma VEGF A (VEGF-A) with PFS in patients with previously untreated mCRC receiving mFOLFOX6-BV or FOLFIRI-BV. Before randomization, patients were stratified by tumoral ERCC1/β-actin mRNA expression level and region.Of 376 enrolled patients, 188 each received mFOLFOX6-BV and FOLFIRI-BV. PFS and overall survival (OS) were comparable between FOLFIRI-BV and mFOLFOX6-BV, with numerically higher PFS [HR = 0.79; 95% CI (confidence interval): 0.61-1.01; P = 0.06] and OS (HR = 0.76; 95% CI: 0.56-1.04; P = 0.09) observed for FOLFIRI-BV. In the high ERCC1 subgroup, PFS and OS were comparable between treatment groups (PFS, HR = 0.84; 95% CI: 0.56-1.26; P = 0.40; OS, HR = 0.80; 95% CI: 0.51-1.26; P = 0.33). Across treatment groups, high plasma VEGF-A levels (>5.1 pg/mL) were observed with shorter PFS (HR = 1.19; 95% CI: 0.93-1.53; P = 0.17) and significantly shorter OS (HR = 1.64; 95% CI: 1.20-2.24; P < 0.01) versus low levels (≤5.1 pg/mL). Safety findings for FOLFIRI-BV or mFOLFOX6-BV were comparable with those reported previously.First-line FOLFIRI-BV and mFOLFOX6-BV had comparable PFS and OS, similar to results in patients with high baseline tumor ERCC1 levels. There were no new safety signals with these bevacizumab-containing regimens." @default.
• W2892367714 created "2018-09-27" @default.
• W2892367714 creator A5000327811 @default.
• W2892367714 creator A5005238877 @default.
• W2892367714 creator A5010582077 @default.
• W2892367714 creator A5015225025 @default.
• W2892367714 creator A5034115525 @default.
• W2892367714 creator A5043241095 @default.
• W2892367714 creator A5044318845 @default.
• W2892367714 creator A5050740210 @default.
• W2892367714 creator A5059156506 @default.
• W2892367714 creator A5080499103 @default.
• W2892367714 creator A5083795244 @default.
• W2892367714 date "2018-09-17" @default.
• W2892367714 modified "2023-09-30" @default.
• W2892367714 title "MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer" @default.
• W2892367714 cites W1963832292 @default.
• W2892367714 cites W1978083619 @default.
• W2892367714 cites W1983040612 @default.
• W2892367714 cites W2096396175 @default.
• W2892367714 cites W2096681299 @default.
• W2892367714 cites W2102883712 @default.
• W2892367714 cites W2111391096 @default.
• W2892367714 cites W2143743735 @default.
• W2892367714 cites W2156214772 @default.
• W2892367714 cites W2157769714 @default.
• W2892367714 cites W2158910681 @default.
• W2892367714 cites W2163731055 @default.
• W2892367714 cites W2193532890 @default.
• W2892367714 cites W2389239223 @default.
• W2892367714 cites W2470575266 @default.
• W2892367714 doi "https://doi.org/10.1158/1078-0432.ccr-18-1221" @default.
• W2892367714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30224341" @default.
• W2892367714 hasPublicationYear "2018" @default.
• W2892367714 type Work @default.
• W2892367714 sameAs 2892367714 @default.
• W2892367714 citedByCount "40" @default.
• W2892367714 countsByYear W28923677142019 @default.
• W2892367714 countsByYear W28923677142020 @default.
• W2892367714 countsByYear W28923677142021 @default.
• W2892367714 countsByYear W28923677142022 @default.
• W2892367714 countsByYear W28923677142023 @default.
• W2892367714 crossrefType "journal-article" @default.
• W2892367714 hasAuthorship W2892367714A5000327811 @default.
• W2892367714 hasAuthorship W2892367714A5005238877 @default.
• W2892367714 hasAuthorship W2892367714A5010582077 @default.
• W2892367714 hasAuthorship W2892367714A5015225025 @default.
• W2892367714 hasAuthorship W2892367714A5034115525 @default.
• W2892367714 hasAuthorship W2892367714A5043241095 @default.
• W2892367714 hasAuthorship W2892367714A5044318845 @default.
• W2892367714 hasAuthorship W2892367714A5050740210 @default.
• W2892367714 hasAuthorship W2892367714A5059156506 @default.
• W2892367714 hasAuthorship W2892367714A5080499103 @default.
• W2892367714 hasAuthorship W2892367714A5083795244 @default.
• W2892367714 hasBestOaLocation W28923677142 @default.
• W2892367714 hasConcept C104317684 @default.
• W2892367714 hasConcept C104451858 @default.
• W2892367714 hasConcept C121608353 @default.
• W2892367714 hasConcept C126322002 @default.
• W2892367714 hasConcept C134935766 @default.
• W2892367714 hasConcept C143998085 @default.
• W2892367714 hasConcept C2776694085 @default.
• W2892367714 hasConcept C2776705615 @default.
• W2892367714 hasConcept C2777802072 @default.
• W2892367714 hasConcept C2779309665 @default.
• W2892367714 hasConcept C2780259306 @default.
• W2892367714 hasConcept C2780456651 @default.
• W2892367714 hasConcept C2780739268 @default.
• W2892367714 hasConcept C2780962732 @default.
• W2892367714 hasConcept C526805850 @default.
• W2892367714 hasConcept C55493867 @default.
• W2892367714 hasConcept C71924100 @default.
• W2892367714 hasConcept C86803240 @default.
• W2892367714 hasConcept C90924648 @default.
• W2892367714 hasConceptScore W2892367714C104317684 @default.
• W2892367714 hasConceptScore W2892367714C104451858 @default.
• W2892367714 hasConceptScore W2892367714C121608353 @default.
• W2892367714 hasConceptScore W2892367714C126322002 @default.
• W2892367714 hasConceptScore W2892367714C134935766 @default.
• W2892367714 hasConceptScore W2892367714C143998085 @default.
• W2892367714 hasConceptScore W2892367714C2776694085 @default.
• W2892367714 hasConceptScore W2892367714C2776705615 @default.
• W2892367714 hasConceptScore W2892367714C2777802072 @default.
• W2892367714 hasConceptScore W2892367714C2779309665 @default.
• W2892367714 hasConceptScore W2892367714C2780259306 @default.
• W2892367714 hasConceptScore W2892367714C2780456651 @default.
• W2892367714 hasConceptScore W2892367714C2780739268 @default.
• W2892367714 hasConceptScore W2892367714C2780962732 @default.
• W2892367714 hasConceptScore W2892367714C526805850 @default.
• W2892367714 hasConceptScore W2892367714C55493867 @default.
• W2892367714 hasConceptScore W2892367714C71924100 @default.
• W2892367714 hasConceptScore W2892367714C86803240 @default.
• W2892367714 hasConceptScore W2892367714C90924648 @default.
• W2892367714 hasFunder F4320332193 @default.
• W2892367714 hasIssue "10" @default.
• W2892367714 hasLocation W28923677141 @default.
• W2892367714 hasLocation W28923677142 @default.
• W2892367714 hasLocation W28923677143 @default.

• next